Endometrial Neoplasms
111
23
33
39
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
14 trials with published results (13%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.0%
10 terminated out of 111 trials
79.6%
-6.9% vs benchmark
7%
8 trials in Phase 3/4
36%
14 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 39 completed trials
Clinical Trials (111)
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
A Study of LY4175408 in Participants With Advanced Cancer
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Registry Platform Ovarian and Endometrial Cancer
A Study of DM002 in Patients With Advanced Solid Tumors
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition